(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066085 A1

(51) International Patent Classification[7]: A61K 38/38, 38/38, 38/18, C07K 14/475, 14/765, 19/00

(21) International Application Number: PCT/IB03/00433

(22) International Filing Date: 7 February 2003 (07.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/355,547 7 February 2002 (07.02.2002) US

(71) Applicants *(for all designated States except US)*: **AVENTIS BEHRING GMBH** [DE/DE]; Emil-von-Behring-Strasse 76, 35041 Marburg (DE). **DELTA BIOTECHNOLOGY LIMITED** [GB/GB]; Castle Court, 59 Castle Boulevard, Nottingham NG7 1FD (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MERTINS, Peter** [DE/DE]; Dornbusch 7, 35041 Marburg (DE). **CELIK, Ilhan** [DE/DE]; Gutenbergstr. 16, 35085 Ebsdorfergrund (DE). **KISKER, Oliver** [DE/DE]; Odenwaldring 44, 64380 Rossdorf (DE). **SLEEP, Darrell** [GB/GB]; 66 Ladybay Road, West Bridgford, Nottingham NG2 5DS (GB). **HAY, Joanna** [GB/GB]; 1 Ridgway, Colyton, Devon EX24 6RP (GB). **HAUSER, Hans-Peter** [DE/DE]; Feuerdornweg 6, 35041 Marburg (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066085 A1

(54) Title: ALBUMIN-FUSED ANTI-ANGIOGENESIS PEPTIDES

(57) Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention." These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention." These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteinsof the invention, as well as vectors containing these nucleic acuds, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.